Hong Kong becomes a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Regulatory Authorities, taking a key step toward building an international hub for medical innovation.

date
20/11/2026
Zhitong Finance APP has learned that on November 20, the Hong Kong Health Bureau announced that Hong Kong, China has officially joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member. The ICH is an important international coordination platform for technical standards in drug regulation. Hong Kong's official membership in the ICH represents international recognition of its drug research and development and regulatory standards, helps further advance the development of the capabilities and mechanisms for "first-tier approval" of innovative drugs, and enables deep participation in the formulation of international rules for drug research and development and registration, accelerating the building of an international healthcare innovation hub.